310 related articles for article (PubMed ID: 34390218)
21. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
Miyashita K; Karayama M; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kono M; Matsui T; Niwa M; Koda K; Toyoshima M; Matsushima S; Matsuura S; Asada K; Fujii M; Kusagaya H; Matsuda H; Inui N; Suda T
BMC Pulm Med; 2021 Oct; 21(1):309. PubMed ID: 34600514
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
[TBL] [Abstract][Full Text] [Related]
25. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
[TBL] [Abstract][Full Text] [Related]
26. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
Dall'Olio FG; Maggio I; Massucci M; Mollica V; Fragomeno B; Ardizzoni A
Lung Cancer; 2020 Jul; 145():95-104. PubMed ID: 32417680
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
[TBL] [Abstract][Full Text] [Related]
28. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
29. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
30. [Peripheral Blood Inflammation Indicators as Predictive Indicators in
Immunotherapy of Advanced Non-small Cell Lung Cancer].
Xia J; Chen Y; Wen S; Du X; Shen B
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials.
Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
J Thorac Oncol; 2019 Aug; 14(8):1440-1446. PubMed ID: 30999110
[TBL] [Abstract][Full Text] [Related]
32. A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Botticelli A; Salati M; Di Pietro FR; Strigari L; Cerbelli B; Zizzari IG; Giusti R; Mazzotta M; Mazzuca F; Roberto M; Vici P; Pizzuti L; Nuti M; Marchetti P
J Transl Med; 2019 Mar; 17(1):99. PubMed ID: 30917841
[TBL] [Abstract][Full Text] [Related]
33. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Boeri M; Milione M; Proto C; Signorelli D; Lo Russo G; Galeone C; Verri C; Mensah M; Centonze G; Martinetti A; Sottotetti E; Pastorino U; Garassino MC; Sozzi G
Clin Cancer Res; 2019 Apr; 25(7):2166-2173. PubMed ID: 30617131
[TBL] [Abstract][Full Text] [Related]
34. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
35. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
[TBL] [Abstract][Full Text] [Related]
36. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
[TBL] [Abstract][Full Text] [Related]
37. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
38. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
39. Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
Li Y; Gong B; Guo Y; Liu W; Chen C; Jiang S; Pan F; Song J; Yang L; Zhou G
BMC Cancer; 2024 Apr; 24(1):535. PubMed ID: 38671373
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
